Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, May 30, 2017 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 2,200,000 shares of its common stock at a price to the public of $20.50 per share. In addition, the underwriters have exercised an option to purchase an additional 330,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by Albireo, with gross proceeds to Albireo of approximately $51.9 million and net proceeds of approximately $48.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.